Daewoong Pharmaceutical’s Nabota, Exposed latest clinical study result and treatment regimen at IMCAS ASIA 2018

Daewoong Pharmaceutical’s Nabota, Exposed latest clinical study result and treatment regimen at IMCAS ASIA 2018 - Aggressively attacking Asian and global markets with outstanding clinical study result and Nabota treatment regimen ‘Nabota(DWP-450)’, a botulinum toxin by Daewoong Pharmaceutical (CEO Sengho Jeon), participated in IMCAS ASIA 2018 held in Bangkok, Thailand from Jul. 13 to 15, and strengthen its footing in the global market. At its 12th anniversary this year, IMCAS ASIA is one of the most prominent international aesthetics conferences. Over 1,650 aesthetics and plastic surgery personnel from 53 countries visited this year and Daewoong Pharmaceutical participated as a gold sponsor and had booth exhibition, symposium and live seminars to promote latest clinical study result and treatment regimen for Nabota. At the symposium, Daewoong Pharmaceutical disclosed cGMP, EU GMP approval for its manufacturing facility for Nabota and presented the result of its large-scale clinical study conducted in US, Europe and Canada that involved over 2,000 subjects. Dr. Hema Sundarm, a dermatologist who participated in the clinical study of Nabota, mentioned at the presentation, “The most important things a clinician looks for in a product are safety and efficacy. Patients must be able to trust the product by checking its evidence. The safety and efficacy of Nabota has been proved by clinical studies conducted in Korea and other advanced nations.” Dr. Jaeyun Jeong, director of Oaro Dermatology demonstrated Nabota and filler regimen and Thai dermatologists, Dr. Atchima Suwanchinda, Dr. Sarawalai Rakchart, and Dr. Mart Maiprasert, also participated as senior demonstrators. Seongsu Park, head of Nabota Business HQ, said, “We are aggressively attacking Asian markets for Nabota through presentation of latest result of clinical study and exhibition PR. We plan to promote Nabota in the global markets continuous evidence-based marketing.” Daewoong Pharmaceutical is exerting efforts to enter into the US market, which occupies over half of botulinum toxin market worldwide. It will not take long until US approval as only step left is to augment the application and documents. #   #   # [Photo] IMCAS ASIA 2018 Nabota Symposium

The release as fetched from its publisher. daewoong.co.kr ↗